Vitamin D + γ-Tocopherol

D3 + γ-T: VDR/RNS/NF-κB ↑/↓, sphingolipids ↓; moderate in prostate/breast/colorectal/bladder.

AI extractedhuman reviewedsources checkedretractions suppressed

🏥⭐⭐ Preclinical — Strong mechanistic base with early human signals; definitive oncology RCTs limited.Calcitriol + γ-tocopherolVitamin D3 + mixed tocopherols

Forms: Combined capsules (2000 IU D3 + 100 mg γ-tocopherol) · Separate supplements (D3 drops + tocopherol oil)

Educational only, not medical advice. OncoForge makes no claim that Vitamin D + γ-Tocopherol treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Key Takeaway

Calcitriol signaling (VDR) promotes differentiation and antiproliferative programs, while γ-tocopherol traps reactive nitrogen species and modulates lipid signaling; together they dampen NF-κB inflammation and enhance apoptosis/autophagy with emerging clinical support.

Evidence at a glance

Tier 2 · animalProstateBreastColorectalBladder

Preclinical VDR/RNS synergy; phase II prostate PSA; meta-QoL modest; ongoing breast/CRC trials; γ-T edges α in RNS data.

How it may work

Vitamin D ligates VDR → p21/p27 induction, cell-cycle arrest, differentiation, and immunomodulation; it also curbs pro-inflammatory cytokines. γ-Tocopherol preferentially scavenges peroxynitrite/RNS, modulates sphingolipid signaling, and contributes to cell-cycle arrest/apoptosis. Combination regimens show additive/synergistic anti-proliferative effects in several tumor models and early human studies.

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

VDR↑Differentiation and cycle arrest
RNS↓Peroxynitrite scavenging
NF-κB↓Inflammatory signaling dampening
Sphingolipids↓Pro-survival lipid modulation
Apoptosis↑Cell death enhancement

VDRRNSNF-κBSphingolipids

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

Doxorubicin: Potentiated activity in breast cancer cells.
Curcumin: Anti-inflammatory synergy in prostate.
Resveratrol: Apoptosis and arrest in colorectal cancer.
Quercetin: Increased apoptosis in breast cancer.

Overlapping mechanisms

VDR ↑: Overlaps calcitriol analogs; monitor Ca.
NF-κB ↓: Redundant with curcumin; inflammation ceiling.

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories

HypercalcemiaGi UpsetKidney Stones

Potential interactions

calcium_supplementsMonitorModerateTheoreticalHypercalcemia risk.
statinsMonitorLowTheoreticalTocopherol may alter lipid effects.
DoxorubicinSynergizeLowTheoreticalAnticancer potentiation in breast.

Timing

With-fatty-meal: Enhances absorption.
QD: Morning for D3 circadian alignment.

References

Research

No published studies for Vitamin D + γ-Tocopherol yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of Vitamin D + γ-Tocopherol depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 2000–5000 IU D3 + 100-400 mg γ-tocopherol/day (po) QD with fatty meal; monitor 25(OH)D, Target 30-50 ng/mL 25(OH)D; γ-tocopherol 200 mg/day; adjust for baseline; co-administer magnesium..

Trials studying Vitamin D + γ-Tocopherol

No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar